Cara Pharma - רווח למניה ב-12 החודשים האחרונים TVRD

סמלים רשמיים של חברת Cara Therapeutics, Inc. (TVRD)

The market valuation dynamics for Cara Therapeutics Inc (TVRD) on the GURU.Markets platform, where the indicator stands at 67.50, reflect the current position of management as they pivot their strategy following setbacks with their lead drug candidate. Cara Therapeutics Inc develops kidney therapies while adhering to fundamental standards within its laboratories. Furthermore, the business invests in wastewater treatment and the safe processing of chemicals to minimize environmental impact.

TVRD: רווח נקי למניה (EPS TTM) Cara Pharma 11.02.2024 - 18.11.2026

caratherapeutics.com - פילוחים אנליטיים ומדדי מפתח (TVRD)

- מחיר שוק ויעדי מחיר של אנליסטים:
הערכת שווי פונדמנטלית של החברה:TVRD - Cara Therapeutics, Inc.
מוצר עיקרי של Cara Therapeutics Inc

This indicator serves as the baseline coordinate axis for assessing the twelve-month growth of earnings per share on a daily basis. The formula measures the rate of change in per-share income, determining the business's historical resilience to economic cycles. By analyzing the annual dynamics of the EPS TTM metric, the investor sees the current value of 67.50, reflecting a critical decline. Amidst workforce reductions and failed clinical trials at Cara Therapeutics Inc (TVRD), this metric confirms that the company is in a stage of deep survival crisis.